Overview
Biosensing tech firm's Q4 revenue grew 13% yr/yr
Adjusted EPS for Q4 beat analyst expectations
Company launched Dexcom G7 CGM system and expanded access in Québec
Outlook
Dexcom expects 2026 revenue between $5.16 bln and $5.25 bln
Company sees 2026 non-GAAP gross profit margin at 63-64%
Dexcom forecasts 2026 adjusted EBITDA margin of 30-31%
Result Drivers
DEXCOM G7 LAUNCH - Co launched Dexcom G7 15 Day CGM system in the U.S., contributing to revenue growth
FDA CLEARANCE - Co received FDA clearance for Dexcom Smart Basal, enhancing product offerings
QUÉBEC EXPANSION - Expanded access to Dexcom CGM in Québec under RAMQ, increasing market penetration
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Adjusted EPS | Beat | $0.68 | $0.65 (23 Analysts) |
Q4 Adjusted Net Income | Beat | $265.10 mln | $259.79 mln (17 Analysts) |
Q4 Adjusted Operating Income | Beat | $331.50 mln | $307.38 mln (21 Analysts) |
Q4 Adjusted Gross Profit | $799.80 mln | ||
Q4 Gross Profit | $792.70 mln | ||
Q4 Operating Income | $323 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 26 "strong buy" or "buy", 4 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Dexcom Inc is $84.41, about 23.9% above its February 11 closing price of $68.15
The stock recently traded at 28 times the next 12-month earnings vs. a P/E of 24 three months ago
Press Release: ID:nBw26wZfxa
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)